Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient took fourth dose of Vivotif eight days after first dose; Case reference number US-BN-2025-000148 is a spontaneous case initially received from consumer via Communication (reference number: USBAV25-0158) on 21-Jan-2025 and concern a *48-year-old* male patient. The patient's medical history and concomitant medication details were not provided. On 05-Jan-2025, the patient took first dose of Vivotif (batch number: unknown) orally, at unknown dose, for pre travel. On 07-Jan-2025, two days after the first dose, the patient took second dose of Vivotif (batch number: unknown) orally, at unknown dose. On 09-Jan-2025, four days after the first dose, the patient took third dose of Vivotif (batch number: unknown) orally, at unknown dose. On 13-Jan-2025, eight days after the first dose, the patient took fourth dose of Vivotif (batch number: unknown) orally, at unknown dose (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of *follow-up* report, it was unknown if the patient experienced any adverse events due Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow-up information received from pharmacist via Communications (USBAV25-0189) on 24-Jan-2025: New information included additional reporter, and patient details.; Reporter's Comments: A 48-year-old male patient took the fourth dose of Vivotif for pre travel, on the day 8 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 48-year-old male patient took the fourth dose of Vivotif for pre travel, on the day 8 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE